TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2020

Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial.

Tim Eisen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.